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Abstract
Crizotinib as the first-generation ALK inhibitor has shown significant activity in ALK-mutated non-small cell lung
cancer (NSCLC). Second- and third-generation ALK inhibitors are entering clinical applications for ALK+ NSCLC. In
addition, a third-generation ALK inhibitor, lorlatinib (PF-06463922), was reported to resensitize NSCLC to crizotinib.
This review provided a summary of clinical development of alectinib, ceritinib, brigatinib (AP26113), and lorlatinib.
Background
Small molecule inhibitors of EGFR (epidermal growth
factor receptor) have been widely used for lung cancer
therapy [1–9]. A small subset (3–13 %) of non-small cell
lung cancer (NSCLC) has been shown to have rearrange-
ments in the ALK (anaplastic lymphoma kinase) gene
[10, 11]. Over the last few years, ALK inhibitors have
shown significant benefits in the management of ALK-
positive NSCLC compared to conventional chemother-
apy [12–15]. A big caveat however is the emergence of
resistance to ALK inhibitors [16]. This article provided a
summary of clinical development of alectinib, ceritinib,
brigatinib (AP26113), and lorlatinib for NSCLC.
ALK gene and the roles in oncogenesis
The ALK gene encodes for ALK receptor tyrosine kinase
enzyme. The gene is located on the short arm of
chromosome 2 (2p23) and belongs to the insulin recep-
tor superfamily. Like other receptor tyrosine kinases, it
has an extracellular domain, a transmembrane segment,
and a cytoplasmic receptor kinase segment [17]. Physio-
logically, ALK is involved in the development of brain
and neurons [18]. It is highly expressed during embryo-
genesis and thereafter becomes dormant. ALK mutation
can lead to tumorigenesis [19]. Most mutations of the
ALK gene are in the form of a translocation with another
partner gene leading to a fusion oncogene which be-
comes overtly expressed in cancers [20] (Fig. 1). The
first ALK mutation was reported in 1994 when NPM-
ALK was described in a subset of anaplastic large cell
lymphomas [21]. This mutation involves fusion of the
nucleophosmin (NPM) gene and ALK as a result of
t(2; 5) (p23; q35) [21, 22]. Additional gene partners
have been discovered in fusion oncogenes with ALK
gene. A few examples are TPM3-t(1;2)(q25;p23), TFG-
t(2;3)(p23;q21), CLTCL1-t(2;17)(p23;q23), and ATIC-
inv(p23;q35) [22]. More mutations of ALK gene have been
reported in several cancers, including NSCLC, inflamma-
tory myofibroblastic tumors, diffuse large B cell lymph-
oma, colon cancer, renal cell carcinoma, breast carcinoma,
esophageal cancer, and neuroblastoma [23].
ALK mutations were first described in NSCLC in 2007
when a subset (7 %) of Japanese patients were found to
have echinoderm microtubule associated protein like-4
(EML4) rearrangement with ALK leading to a fusion
oncogene EML4-ALK [24, 25]. This was due to an inver-
sion rearrangement from inv(2) (p21;p23). As a result,
EML4 replaces the extracellular and intramembranous
parts of ALK and fuses with the juxta membranous part.
The EML4-ALK gene induced tumor formation in nude
mice [23, 24]. Due to different breakpoint on EML4,
several variants of EML4-ALK mutation have been
described [10, 26, 27]. EML4-ALK variants with differing
frequencies are V1 (54.5 %), V2 (10 %), V3a/V3b (34 %),
and V5a (1.5 %) [26, 27]. Rearrangements of the ALK gene
with partner genes other than EML4 have been described,
namely, KIF5B, KLC1, TFG, TPR, HIP1, STRN, DCTN1,
SQSTM1, and BIRC6 [28] (Fig. 1).
ALK translocations result in increased tyrosine kinase
activity leading to increased cell proliferation and sur-
vival and ultimately tumorigenesis. The ALK signaling
pathways involve phospholipase Cγ (PLCγ), Janus kinase
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(JAK)–signal transducer and activator of transcription
(STAT), PI3K–AKT, mTOR, sonic hedgehog (SHH),
JUN-B, CRKL–C3G (also known as RAPGEF1), RAP1
GTPase, and MAPK signaling cascades [23].
ALK+ NSCLC characteristics
ALK-positive NSCLCs are generally seen in non-smokers,
occur at a younger age, and are mostly adenocarcinoma in
histology [15]. They also seem to have a female gender pre-
disposition [11–13, 27]. Pathological features include solid
morphology and presence of signet ring cells [29, 30].
Crizotinib (PF-02341066, xalkori)
Crizotinib (PF-02341066, xalkori) is the first-generation
ALK inhibitor approved for ALK-positive NSCLC [12]. It
has a IC50 against EML4-ALK of 250–300 nm [31]. In
addition to having activity against ALK, it also has activity
against c-MET and ROS1 tyrosine kinases [31–34]. It
was approved for ALK positive, locally advanced, and
metastatic NSCLC [35].
The PROFILE 1007 study involving 347 patients with
ALK-positive NSCLC compared crizotinib with chemo-
therapy in patients who failed at least one prior
platinum-containing regimen [13]. These patients were
randomly assigned to receive either 250 mg twice daily
of oral crizotinib vs intravenous pemetrexed or doce-
taxel. The median PFS was 7.7 months (95 % CI 6.0–8.8)
in crizotinib group compared with 3.0 (95 % CI 2.6–4.3)
months in the chemotherapy group. The ORR was 65 %
(95 % CI 58–72) in crizotinib compared to 20 % (95 %
CI 14–26) in the chemotherapy group (P < 0.001) [13].
The adverse events reported were mostly grades 1 or 2.
Grade 3 or 4 events were elevated aminotransferase
levels and neutropenia which occurred in 16 and 13 %
of patients, respectively [13, 15].
PROFILE 1014 study compared crizotinib vs chemo-
therapy in 343 patients who had no previous treatment
for advanced NSCLC. They were randomized to either re-
ceive crizotinib vs pemetrexed plus platinum (cisplatin or
carboplatin). Progression-free survival for crizotinib group
(n = 172) was 10.9 months and for chemotherapy group
(n = 171) was 7.0 months. The ORR was 74 % (95 % CI
67–81) for crizotinib group vs 45 % (95 % CI 37–53) for
chemotherapy (P < 0.001). Median OS was not reached in
either group at the time of report (hazard ratio for death
with crizotinib, 0.82; 95 % CI, 0.54 to 1.26; P = 0.36); the
1-year estimated survival was 84 % with crizotinib vs 79 %
with chemotherapy. Crizotinib-associated AEs were vision
disorders, diarrhea, nausea, and edema. It was concluded
from PROFILE 1014 study that crizotinib was superior to
standard first-line pemetrexed-plus-platinum chemother-
apy in patients with previously untreated advanced ALK-
positive NSCLC. Hence, crizotinib is currently approved
for first line in ALK+ NSCLC [14, 36].
Crizotinib has also been shown to be highly efficacious
in ROS1-positive NSCLC which comprises 1 % of all
NSCLC. In a phase 1 study of 50 patients, the ORR was
72 % (95 % CI 58–84) (33 PR and 3 CR). The median
PFS was 19.2 months [31]. Among 30 tumors that were
tested, 7 ROS1 fusion partners were identified, 2 of these
partner genes were novel. However, there was no correl-
ation between the type of ROS1 rearrangement and the
clinical response to crizotinib. ROS1 rearrangement mo-
lecularly marks a small subgroup of NSCLC for which
crizotinib can play an active role in clinical therapy.
Limitations of crizotinib
Resistance to crizotinib
Majority of patients develop resistance to crizotinib
within 1 to 2 years from the initiation of therapy [37].
The resistance to ALK inhibitors can be classified into
primary and secondary resistance [38].
Primary resistance is seen when the tumor is deemed
refractory to the agent at the beginning of the therapy
Fig. 1 ALK mutations in non-small cell lung cancer. Most mutations of the ALK gene are in the form of a translocation with another partner gene
leading to a fusion oncogene. Most common fusion oncogenes in non-small cell lung cancer are presented in this diagram
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itself as reported in chronic myeloid leukemia [39]. In
the case of ALK+ NSCLC, the primary resistance can be
attributed to the different fusion variants of EML4 with
ALK or other partner genes [38]. Different sensitivities
to crizotinib have been shown to be dependent upon the
ALK variant or fusion gene partner [40, 41]. Currently,
FISH has been the gold standard for detecting ALK mu-
tations in NSCLC.
Secondary resistances are acquired mechanisms after
the tumor has been exposed to an ALK inhibitor and
can be further classified into two categories: ALK dom-
inant and ALK non-dominant. In the ALK dominant
type, there is mutation in the target ALK gene resulting
in inability to inhibit the encoded tyrosine kinase. These
are termed as ALK dominant as they depend upon ALK
tyrosine kinase activity [42]. Most of the mutations are
in the form of point mutations and the first ones to be
described are C1156Y and L1196M [43]. There have
been several other secondary point mutations that have
been identified and are the following: G1269A, F1174L,
1151Tins, L1152R, S1206Y, I1171T, G1202, D1203N,
and V1180L [41–44].
The ALK non-dominant resistance involves emergence
of bypass tracks such as EGFR mutation, KRAS muta-
tion, amplification of KIT, phosphorylated amplification
of ErbB, MET, and activation of IGF-1R in the down-
stream signaling. It has been shown that in the same
ALK resistant tumor, multiple mechanisms of resistances
may occur [42, 45].
Secondary mutations of the ALK gene result in 29 %
of resistant cases, and gene amplification is implicated in
9 % of these cases. The remaining of the cases can be at-
tributed to bypass pathways and other mechanisms that
have yet to be defined [46].
CNS metastasis
Crizotinib has poor activity against CNS metastasis in
NSCLC as evidenced by low concentrations detected in
CNS samples during the course of systemic chemother-
apy. The ratio of CNS to serum concentration of crizo-
tinib has been in the range of 0.0006–0.001 as established
by individual case reports [47–49]. In a retrospective ana-
lysis of trials involving crizotinib, 20 % of patients who did
not have CNS disease at the beginning had CNS metasta-
sis while on therapy [50]. PF-06463922 (lorlatinib) is a
newly developed ALK inhibitor that has been designed for
better CNS penetration and is currently in phase I/II trials
(NCT01970865) (see below) [15].
In another analysis of 90 patients with brain metasta-
ses from ALK-mutated NSCLC, 84 of 90 patients re-
ceived radiotherapy to the brain, and 86 of 90 received
TKI therapy [51]. Significant improvement in this popu-
lation of poor-prognostic patients was reported. The me-
dian OS after development of brain metastases was
49.5 months (95 % CI, 29.0 months to not reached), and
median intracranial PFS was 11.9 months (95 % CI, 10.1
to 18.2 months). Four groups of patients were classified
in this analysis with distinct outcomes: absence of extra-
cranial metastases, high Karnofsky performance score
≥90, and no prior therapy with TKIs before development
of brain metastases had longer survival (P = .003, <.001,
and <.001, respectively), whereas isolated brain metastasis
or initial treatment with radiation were not (P = .633 and
.666, respectively). It was concluded that brain radiother-
apy and TKIs to control intracranial disease in ALK+
NSCLC can lead to prolonged survival. Newer TKIs are
playing an important role in this population of patients.
Crizotinib toxicity
There have been case reports of significant adverse
effects that were not reported in the initial trials.
These included erythema multiforme [52], acute inter-
stitial lung disease [53, 54], renal polycytosis [55–57],




Within the first year or two after crizotinib treatment is
initiated, resistance typically arises. As mentioned above,
mechanisms commonly include secondary mutations
within the ALK tyrosine kinase domain and activation of
alternative signaling pathways. More potent and struc-
turally different inhibitors are therefore developed.
Ceritinib (LDK378, zykadia) is a potent ALK inhibitor
compared to crizotinib [60–62]. A phase I study with
130 patients with ALK-positive advanced tumors in-
cluded 122 NSCLC [63]. The doses were 50 to 750 mg
in the dose escalation phase which enrolled 59 patients.
The MTD of ceritinib was shown to be 750 mg daily.
The dose-limiting toxicities (DLT) were diarrhea, vomit-
ing, dehydration, elevated aminotransferase levels, and
hypophosphatemia. Seventy-one patients received ceriti-
nib in the dose expansion phase. One hundred fourteen
patients received ceritinib dose of at least 400 mg daily.
The ORR was 58 % (95 % CI 48–67). Among the 80 pa-
tients who failed crizotinib, the response rate was 56 %
(95 % CI, 45 to 67). Among patients with NSCLC who
received ceritinib with doses 400 mg or higher, the me-
dian PFS was 7.0 months (95 % CI, 5.6 to 9.5).
Thus, this study proved that ceritinib induced high re-
sponses in patients who failed crizotinib. Ceritinib was
approved for treatment of relapsed or refractory NSCLC
after crizotinib [64] (Table 1).
Alectinib
Alectinib (CH5424802, alecensa) is a potent and highly
selective inhibitor of ALK tyrosine kinase with IC50 of
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1.9 nM [65, 66]. More importantly, it has activity against
L1196M which is one of the commonly seen secondary
mutations in ALK gene leading to resistance to crizotinib.
In a multicenter, single-arm, open-label phase 1–2
study conducted in Japan (AF-001JP), ALK inhibitor
naïve patients who had ALK-positive NSCLC were
treated with alectinib [67]. In the dose escalation phase
which included 24 such patients, increasing doses in the
20–300 mg range were used. No dose-limiting toxicities
(DLT) were noted. Hence, 300 mg twice daily was estab-
lished as the recommended dose for phase II. The phase
II portion enrolled 46 patients. Forty-one of these pa-
tients had PR and 2 had CR. Hence, ORR was around
94 % (95 % CI: 82-98). Grade 3 adverse events were re-
ported in 26 % (n = 12) and included elevated creatinine
phosphokinase and neutropenia [67].
In another phase 1–2 single-arm open-label study, 47
patients with ALK-positive NSCLC who had resistance
to crizotinib or were intolerant were treated with alecti-
nib [68]. In the dose escalation phase, doses were esca-
lated from 300 to 900 mg in seven different cohorts of
patients. DLTs were seen in the 900-mg cohort: grade 3
headache in one patient and grade 3 neutropenia in an-
other one. Three patients dropped out of the study due
to adverse events: grade 3 dyspnea, grade 4 CNS metas-
tasis, and grade 3 abdominal pain. Out of the 47 pa-
tients, 44 were assessed for response and the ORR was
found to be 55 % (24 PR, one CR). ORR for the 21 pa-
tients who had baseline CNS metastasis was 52 % (5 CR
and another 6 having partial CNS response). Therefore,
this study showed that alectinib not only was effective in
patients pretreated with first-generation ALK inhibitor
but also was active for CNS metastasis [68]. Alectinib is
now FDA-approved for the treatment of metastatic ALK
+ NSCLC in patients who have progressed on or are in-
tolerant to crizotinib.
Brigatinib (AP26113)
Brigatinib is another second-generation ALK inhibitor. It
is a potent dual inhibitor of ALK and EGFR, including
ALK L1196M and EGFR T790M mutants, shown in pre-
clinical and first-in-human studies [69–71]. In the initial
dose-finding study, there were 18 evaluable ALK+ pts.
Among these patients, 10 responded. Fifteen ALK+ pts
had 0 (n = 3) or 1 (n = 12) prior ALK TKI (crizotinib); of
these, 8/12 pts (67 %) responded, including two complete
responses. Radiographic improvement was seen in 4 of 5
ALK+ pts with untreated or progressing CNS lesions.
There were 16 pts enrolled with EGFRm history (15
NSCLC, 1 SCLC); 14 pts had ≥1 prior EGFR TKI. Of 12
EGFRm pts with a follow-up scan, 1 pt (prior erlotinib)
responded at 120 mg, 6 pts had stable disease.
In the last update of the phase I/II single-arm, open-
label, multicenter study in patient pts with advanced ma-
lignancies (NCT01449461), patients received brigatinib
as the following: phase I: 30–300 mg/day total daily
dose; phase II: 90 mg/day, 180 mg/day, or 90 mg/day
for 7 days followed by 180 mg/day. Safety was re-
ported in all 137 treated pts; efficacy was evaluated in
all 79 ALK+ NSCLC pts [72] (Table 2). Most common
treatment-emergent adverse events (TEAE) included nau-
sea, diarrhea, fatigue, cough, and headache. Early-onset
Table 1 FDA approved ALK inhibitors for non-small cell lung cancer





















Phase I Failed chemotherapy and crizotinib Ceritinib (NSCLC, ≥400 mg) 114 58 % 7.0 ms N/A [63]
Phase I/II Failed chemotherapy and crizotinib Alectinib (phase II) 46 94 % NA N/A [67]
Phase I/II Failed chemotherapy and crizotinib Alectinib (phase II) 47 55 % NA N/A [68]
Abbreviations: N/A not applicable, No. number, ORR overall response rate, DOR duration of response, PFS progression-free survival, Ref reference, wks weeks,
ms months
Table 2 Brigatinib and lorlatinib in clinical development for non-small cell lung cancer

















N/A N/A N/A [77]
Abbreviations: N/A not applicable, ORR overall response rate, DOR duration of response, PFS progression-free survival, Ref reference, wks weeks, m months,
ALKi ALK inhibitor
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pulmonary events were observed less frequently with the
90-mg starting dose compared with higher doses. Median
progression-free survival (PFS) is 56 weeks, 47 weeks with
prior crizotinib. In pts with baseline CNS metastases, half
of 12 pts had a brain response and 8/26 pts with only
non-measurable lesions had disappearance of all lesions.
Median intracranial PFS for these pts is 97 weeks. There-
fore, brigatinib was active in crizotinib-resistant NSCLC
and showed activity in CNS lesions. A randomized phase
2 trial of brigatinib in crizotinib-resistant ALK+ NSCLC
(ALTA) is underway.
Third-generation ALK inhibitor
Lorlatinib (PF-06463922) is a novel, reversible, potent
ATP-competitive small molecule inhibitor of ALK and
ROS1. This third-generation inhibitor is effective against
all known resistant mutants [73–75]. In preclinical studies,
lorlatinib was proven to be active in crizotinib-resistant
cancers both in vitro and in xenograft models [73–75].
To overcome ALK mutations and ALK inhibitor resistance,
lorlatinib was combined with PI3K pathway inhibitors, such
as PF-05212384 (PI3K/mTOR), GDC0941 (pan-PI3K),
or GDC0032 (beta-sparing). Such rational combination
was reported to lead to more robust activity in vitro and
greater duration of efficacy in vivo in the ALK inhibitor
resistant models [76].
Lorlatinib is being studied in a phase I clinical trial in
patients who were refractory to crizotinib and ceritinib
(NCT01970865) [77]. One patient enrolled to this trial
responded to lorlatinib for 8 months. Interestingly, the
patient was resensitized to crizotinib after the patient
failed the lorlatinib treatment, indicating that retreat-
ment under molecular guidance can be a clinically
meaningful approach.
Conclusions
Second- and third-generation ALK inhibitors are enter-
ing clinical applications for ALK+ NSCLC. Among these,
dual inhibitors targeting ALK as well as EGFRm and
ROS1 may provide additional benefits for crizotinib-
refractory patients. Resensitization to and retreatment
with crizotinib can be considered under molecular guidance.
More and more biomarker-targeted agents are entering
clinical applications [78–81]. Immune therapies are showing
remarkable benefits [82–91]. It is foreseeable that combin-
ation of these novel agents and small molecular inhibitors
may expand the potential for treatment of refractory lung
cancer patients.
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